NomoCan Pharmaceuticals is focused on developing innovative therapies for aggressive cancers, particularly through its platform technology that enables both diagnostic and therapeutic advancements. The company has created a selective and specific diagnostic test aimed at the early detection of cancers, which is crucial for improving patient outcomes. Additionally, NomoCan is pioneering the use of monoclonal antibody (mAb) drugs, which are designed to target specific cancer markers, thereby enhancing the precision of cancer treatment and offering hope to patients facing these challenging diseases.

One of the key products in NomoCan's pipeline is NMC-001, a monoclonal antibody that specifically targets a marker associated with pancreatic cancer. This antibody not only aids in the accurate identification and diagnosis of pancreatic cancer but also exhibits significant anti-tumor efficacy in preclinical rodent models. The development of NMC-001 underscores NomoCan's commitment to addressing the high unmet medical needs in oncology, particularly for conditions like pancreatic cancer, which has a notably low survival rate and high mortality.

United States

NomoCan Pharmaceuticals offers first-in-kind targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, it introduces a highly effective therapeutics for the treatment of various cancers in order to “Bring Hope” to patients affected by this devastating disease.​

NomoCan Pharmaceuticals

Company Details